New HPV Vaccine Making Girls In UK Sick

Philadelphia Bulletin

By Susan Brinkmann, For The Bulletin
Sunday, September 20, 2009

Top Stories

A new cervical cancer vaccine, dubbed the “promiscuity jab” in the UK, is responsible for more than 2,000 complaints since the government began administering it to female teens last year. The same drug is currently under consideration by the Food and Drug Adminstration (FDA) for use in the U.S.

Cervarix, manufactured by GlaxoSmithKline, competes with Merck’s more expensive Gardasil vaccine in the UK where more than a million teens have already received it as part of a government program. The new drug, which is administered in three doses, targets two HPV strains that cause cervical cancer – HPV 16 and HPV 18.

But after a year of use, the track record for Cervarix does not appear to be much better than the problem-strewn Gardasil.



Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.